Zimar, eye drops 0.3%, 5 ml

Zymar is an antimicrobial drug of the group of fluoroquinolones. The bactericidal effect of gatifloxacin, as well as other fluorinated quinolones, is due to its ability to block the bacterial enzyme DNA-gyrase. DNA-gyrase is an important enzyme involved in replication, transcription and repair of bacterial DNA. Gatifloxacin also inhibits topoisomerase IV, which plays a key role in chromosomal DNA division during bacterial cell division. The antibacterial spectrum of the drug covers penicillin-, aminoglycoside- and cephalosporin-resistant microorganisms as well as multidrug-resistant ones.

Active against Gram-positive microorganisms: Staphylococcus aureus, Streptococcus pneumoniae (including penicillin-sensitive and penicillin-resistant strains), Streptococcus pyogenes, Streptococcus saprophyticus, Staphylococcus epidermidis (meticillin-sensitive strains), Streptococcus spp. (groups C, G , F), Streptococcus agalactiae; Gram-negative microorganisms: Escherichia coli, Haemophillus influenzae (including β-lactamase producing strains), Haemophillus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis (including β-lactamase producing strains), Neisseria gonorrhoeae (including β-lactamase-producing strains), Proteus mirabilis, Acinetobacter iwoffii, Citrobacter koseri, Citrobacter freundii, Enterobacter aerogenes, Enterobacter cloacae, Klebsiella oxytoca, Moragnella morganii, Proteus vulgaris; other microorganisms: Chlamydia pneumoniae, Legionella pneumophila, Mycoplasma pneumoniae.

The drug also has high activity against anaerobes, in particular Peptostreptococcus spp.

Pharmacokinetics

After instillation of 0.3% gatifloxacin eye drops, plasma concentration values of gatifloxacin remain below the threshold of analytical determination (5 ng/mL).

Indications

The therapy of bacterial conjunctivitis that is caused by pathogens sensitive to gatifloxacin.

Active ingredient

Composition

Excipients

Benzalkonium chloride 0.05 mg,

dinatrium edetate dihydrate 0.1 mg,

sodium chloride 8.6 mg,

Hydrochloric acid to pH 5.8-6.0,

sodium hydroxideo pH 5.8-6.0,

water to 1 ml.

How to take, the dosage

Topically. The drug is injected while the patient is awake.

The 1st and 2nd day, 1 drop in the affected eye every 2 hours, up to 8 times a day.

On days 3 to 7, 1 drop up to 4 times a day.

Interaction

Systemic drug interactions are unlikely due to the low concentration of the main active ingredient gatifloxacin in blood plasma after topical administration.

Special Instructions

The use of the drug requires mandatory consultation with a specialist.

The use of Zimar eye drops over 28 days, as well as other antibacterial agents, may lead to the development of microorganisms and fungi insensitive to its action. If superinfection occurs, the drug should be discontinued and replaced with an alternative therapy.

The use of contact correction (lenses) is not recommended during treatment with the drug.

Zymar should not be used for subconjunctival injections, or injected into the anterior chamber of the eye.

Avoid contact of the tip of the dropper bottle with any surface, including the mucous membrane of the eyes, skin of the hands, etc.

Contraindications

The drug may be given with caution:

Side effects

Digestive system disorders: nausea, vomiting, abdominal pain, anorexia, diarrhea, constipation, dyspepsia, flatulence, gastritis, glossitis, stomatitis, gingivitis, gastrointestinal bleeding.

NS and peripheral nervous system disorders: Headache, dizziness, migraine, insomnia and other sleep disturbances, agitation, anxiety, nervousness, confusion, drowsiness, paresthesias, tremors, seizures, lower limb muscle cramps, depersonalization, depression, panic attacks, paranoia, hostility, photophobia, ataxia, hyperesthesia, visual disturbances, eye photosensitivity, distortion of taste, parosmia, peripheral neuropathy.

Cardiovascular system disorders: tachycardia, bradycardia, arterial hypertension.

Muscular system disorders: increased risk of tendon rupture, ossalgia, arthritis.

Respiratory system: hyperventilation, bronchospasm.

Allergic reactions: facial edema, edema of the mucous membrane of the mouth and tongue, generalized edema, maculopapular rash, vesiculobullet rash.

Others: chest pain, ear pain, thirst, dry skin, fever, vaginitis, hypoglycemia, hematuria, metrorrhagia.

Overdose

Theoretical possibility of overdose with Zimar eye drops exists.

Treatment: Rinse eyes with warm running water to remove excess product.

Pregnancy use

In the absence of adequate and rigorously controlled studies in pregnant women, Zimar should be used with caution in pregnancy and only if the expected benefit to the mother exceeds the potential risk to the fetus.

It has been confirmed that when gatifloxacin is used topically in the form of eye drops, its systemic plasma concentration is low, so no effect on breastfed children is expected.

If Zimar is prescribed during lactation, however, breastfeeding should be stopped for the duration of treatment, because excretion of the drug in breast milk has not been studied with topical administration.

It is contraindicated in children under one year of age.